Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00744237 · ClinicalTrials.gov registry record · Phase 4

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

A Phase 4 study, sponsored by Forest Laboratories.

Completed
Registry status
Phase 4
Development phase
231
Enrollment target

NCT00744237 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 231 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00744237, a Phase 4 study, has completed, sponsored by Forest Laboratories.

COMPLETED
Registry status
Phase 4
Development phase
231 participants
Enrollment target

Study Summary

This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus

Interventions

  • DRUG Nebivolol
  • DRUG HCTZ
  • DRUG Metoprolol ER

Trial Details

FieldValue
Enrollment Target 231 participants
Start Date 2008-08
Phase Phase 4

Sponsor

Forest Laboratories

145 total trials

What the Registry Record Tells You About NCT00744237

The ClinicalTrials.gov registry entry for NCT00744237 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Nebivolol is the first listed.

NCT00744237 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00744237 about?

NCT00744237 is a clinical study titled "Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients". This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus

What is the current status of trial NCT00744237?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 231 participants. The study started on 2008-08.

What interventions are being tested in trial NCT00744237?

The interventions under investigation include: Nebivolol (DRUG), HCTZ (DRUG), Metoprolol ER (DRUG).

Who is sponsoring clinical trial NCT00744237?

This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.